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Unresectable Parathyroid Carcinoma
ABSTRACT
Background: Severe hypercalcemia is the leading cause of death in patients 
with parathyroid carcinoma. Non-curative resection and pharmacological 
measures may be useful for palliation in cases with recurrent and metastatic 
disease. Palliative treatment with intra-neoplastic ethanol injection has not 
been reported yet. Methods: Ultrasound-guided percutaneous alcohol injec-
tion in one patient with unresectable parathyroid carcinoma is reported. Re-
sults: One male patient with extensive recurrent parathyroid carcinoma 
suffering from severe hypercalcemia, refractory to all available medical mea-
sures has undergone two percutaneous ethanol injections. No major compli-
cations ensued and parathormone levels decreased from 2,990 pg/mL to 
2,230pg/ml after the first injection, and to 1,104pg/mL after the second one. 
Calcium levels decreased from 19.8 mg/dL to 16.1 mg/dL and to 14.5 mg/dL, 
respectively. The patient died of metabolic hypercalcemia complications about 
two months later, probably due to mediastinal disease progression. Conclu-
sion: Ultrasound-guided percutaneous ethanol injection may be employed to 
palliate parathyroid carcinoma in selected cases, with a transitory decrease in 
PTH and calcium levels. Arq Bras Endocrinol Metab 2008; 52/4:707-711)
Key-words: Hyperparathyroidism, primary; Parathyroid neoplasms; Parathyroid 
hormone; Parathyroid glands; Hypercalcemia; Ultrasonography, Interventional.
RESUMO
Injeção Percutânea de Etanol Guiada por Ultra-Sonografia para Paliação de 
Carcinoma de Paratireóide Não-Extirpável.
Introdução: A hipercalcemia severa é a principal causa de óbito nos pacientes 
com carcinoma de paratireóide. Em casos com recidiva ou doença metastática 
inoperáveis, a ressecção não curativa e as medidas farmacológicas podem ser 
úteis para a paliação. O presente estudo relata a experiência com a injeção de 
etanol na neoplasia para tratamento paliativo em um caso. Método: Relato da 
injeção percutânea de etanol em paciente com carcinoma de paratireóide re-
cidivado, não passível de ressecção. Resultado: Paciente masculino com hiper-
calcemia refratária a tratamento clínico decorrente de recidiva local não 
extirpável de carcinoma de paratireóide. Submetido a duas sessões de injeção 
percutânea de etanol. Não houve complicações maiores. Após a primeira in-
jeção, o nível de paratormônio reduziu-se de 2.990 pg/mL para 2.230 pg/ml. 
Após a segunda injeção, o nível caiu para 1.104 pg/mL. A calcemia declinou de 
19,8 mg/dL para 16,1 mg/dL e 14,5 mg/dL, respectivamente. O paciente faleceu 
de complicação metabólica, cerca de dois meses depois, possivelmente pela 
progressão da doença no mediastino. Conclusão: A injeção percutânea de 
etanol pode ser utilizada para paliação do carcinoma de paratireóide em casos 
selecionados, com queda transitória do nível de hormônio da paratireóide e da 
calcemia. Arq Bras Endocrinol Metab 2008; 52/4:707-711)
Descritores: Hiperparatireoidismo primário; Neoplasias das paratireóides; 
Hormônio paratireóideo; Glândulas paratireóides; Hipercalcemia; Ultra-sonogra-
fia de intervenção.
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INTRODUCTION
PARATHYROID CARCINOMA IS considered a rare disease, comprising less than 1% of patients with primary 
hyperparathyroidism in some series (1). A relatively hi-
gher incidence was reported in Italy and Japan (2). In 
Brazil (3), although the incidence reached 6.1% at the 
University of Sao Paulo Medical School from 1995 to 
2000, the incidence dropped to 1.9% from 1996 to 
2005, probably due to the increased diagnosis and sur-
gical treatment of less symptomatic parathyroid adeno-
ma patients.
In some series, the clinical presentation of para-
thyroid carcinoma was not different from that of para-
thyroid adenoma (4). Conversely, some authors 
reported that patients with parathyroid malignancy 
usually presented marked hypercalcemia and a palpable 
mass (1-3). This information may help the surgeon du-
ring cervical exploration, in order to perform a comple-
te operation, and to avoid recurrence (5). Recurrence is 
rarely curable, and death is frequently related to severe 
hypercalcemia (6). Although rarely curable, recurrence 
may be treated by radical surgery to alleviate hypercal-
cemia (7). Postoperative radiotherapy may be effective 
as an adjuvant treatment for microscopic residual dise-
ase or for close margins (8). but apparently it is not 
effective for gross residual disease. Similarly, chemothe-
rapy is not successful (9). 
When all conventional therapeutic measures have 
failed to control the tumor, clinical management of 
hypercalcemia is recommended to postpone death. Pa-
renteral bisphosphonates and cinacalcet are the most 
effective available drugs to lessen the catastrophic effect 
of excessive parathyroid hormone (PTH) (10). A very 
impressive result of anti-PTH immunization was repor-
ted, achieving not only metabolic control but also me-
tastases regression (11). To our knowledge, palliative 
treatment of parathyroid carcinoma with ethanol injec-
tion has not previously reported in literature, and the 
experience observed in one case is here discussed.
PATIENT REPORT
In December 1998, a 50 year-old man went to our Ins-
titution with a two-month history of spontaneous rib 
fracture and asthenia. He has complained of renal sto-
nes for the past ten years and reported a thyroid opera-
tion 20 years ago. He had a palpable cervical mass, 
associated with total calcium level of 13.2 mg/dl (nor-
mal range 8.5-10.5mg/dl) and a PTH of 625 pg/ml 
(normal range 13 to 54 pg/ml). A computerized to-
mography showed a mass behind the left thyroid lobe, 
extending to the retropharyngeal space. With a clinical 
suspicion of parathyroid carcinoma, the patient was 
submitted to a presumed complete resection including 
the left thyroid lobe and left tracheoesophageal groove 
lymph node resection. The thyroid lobe was grossly in-
vaded and seven lymph nodes were negative. The para-
thyroid tumor measured 8.0 x 5.0 x 3.0 cm. 
Unfortunately, the final pathology report disclosed po-
sitive microscopic retropharyngeal surgical margin. 
PTH level decreased to 1.6 pg/ml (normal range 12 to 
72 pg/ml), and calcium supplements were necessary, as 
hungry bones syndrome ensued. Based on previous 
institutional experience with radiotherapy for para-
thyroid carcinoma, only a watchful policy was advised. 
The patient had no evidence of disease on follow up 
evaluation in May 1999, with normal both total and 
ionized serum calcium. 
He had been away until his next follow up in Sep-
tember 2000, when total calcium was of 13,2mg/dl and 
PTH was elevated at 353 pg/ml. Imaging work-up re-
vealed an extensive recurrence in retropharyngeal space 
from the right side to the left, extending to mediastinum 
and involving esophagus and the membranous portion 
of the trachea. He underwent palliative sessions of pami-
dronate, with initial good response. At the end of 2001, 
he was refractory to medical therapy, and his clinical con-
dition deteriorated, having anemia and decline of renal 
function. At this time, calcium blood level was 18.0mg/
dl. At laryngoscopy, the right vocal cord palsy was obser-
ved and a palliative resection of the right side mass was 
performed. A 6.5x 4.0x 4.0 cm mass was excised, cau-
sing a small pharyngeal defect, which was closed prima-
rily, with no further complication. Graphic 1 depicts the 
marked decrease of PTH, which was accompanied by a 
calcium decline to 12.6mg/dl. Postoperatively, confor-
mational radiotherapy was used,, totalling 7,020 cGy, 
associated with two cycles of 400mg/m2 dacarbazide. 
He received a monthly dose of 90 mg of pamidronate. 
His condition was stable until October 2003, when cal-
cium reached 19.8mg/dl and he was unresponsive to 
pamidronate and saline hydration with forced diuresis. It 
was considered the possibility to develop a vaccine 
against the tumor or PTH, but the technology was una-
vailable at our Institution at that time. The surgeons au-
thoring this paper considered the possibility of another 
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Graphic 1. PTH levels during patient’s disease evolution.
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palliative resection, but the procedure was not accepted 
by the majority of other staff surgeons at the tumor bo-
ard meeting.
After signing an informed consent, he underwent 
two separate sessions of 95% ethanol injection under 
ultrasound guidance with a 23-day-interval. The in-
jections were performed by an experienced radiologist 
(MCC). In both sessions a surgeon was present. In 
the first evaluation with Doppler ultrasound, well vas-
cularized masses of 9.3 ml on the right side and of 
16.6 ml on the left side were observed. Volumes of 
2.5 ml and 1.2 ml were injected on the right side and 
left side, respectively. The patient complained of tole-
rable pain during the procedure. No local or systemic 
complications related to ethanol were observed. PTH 
levels were of 2,230pg/ml after the first injection and 
calcium levels decreased from 19.8 mg/dL to 16.1 
mg/dL. On the second procedure, volumes of 8.9ml 
on the right side and 15.0 ml on the left were seen. 
Under sedation with midazolam, 4.5 ml of ethanol 
were injected in the right tumoral mass, but only 0.3 
ml on the left side, as the patient refused any further 
injection. No complication ensued. Although a signi-
ficant volume of the lesion was on the left side, it was 
preferred to use larger volumes on the right side whe-
re recurrent laryngeal nerve was previously sacrificed. 
Although there was a marked decrease in PTH levels, 
as show in graphic 1, calcium levels remained around 
14.5 mg/dl. Two months later, PTH and calcium 
started to rise again, probably due to the progression 
of the tumor. His clinical condition became critical 
and he died soon after.
This patient was included in a previous communi-
cation (3), but details of his treatment were not pre-
viously described.
DISCUSSION
In spite of its rarity, parathyroid carcinoma is still a the-
rapeutic challenge (12). The etiology is unknown and 
surgery is the single most effective therapy when com-
plete resection is achieved at the time of initial opera-
tion. Thus, preoperative suspicion and intraoperative 
recognition are of paramount importance (13). In the 
present case, even though a preoperative and intraope-
rative suspicion led to a presumed complete operation, 
there was microscopic residual disease. Retrospectively, 
adjuvant radiotherapy should be advised at that mo-
ment, to prevent tumor regrowth (13). 
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In 2005, Kameyama and Takami suggested that 
parathyroid carcinoma should be divided in low-grade 
(i.e., minimally invasive type) and high-grade (i.e., wi-
dely invasive type) (14). The experience in the present 
case concurs with their opinion. In 1999, Shaha and 
Shah proposed a staging system for parathyroid carci-
noma (12). According to their system, the present case 
would be staged as T3 (“primary tumor of any size 
with invasion of the surrounding soft tissues, such as 
the thyroid gland and strap muscles”). If this staging 
system is to be adopted, T4 should include any high 
grade-tumor and not only those with “massive central 
compartment disease invading the trachea and esopha-
gus or recurrent parathyroid carcinoma” (12).
Alcohol injection is clearly not the therapy of choi-
ce for parathyroid disease, but there are some relative 
indications in a very small number of selected patients 
(15). This technique may be helpful to palliate metabo-
lic complications of parathyroid carcinoma. A marked 
decrease of PTH was observed in the present case. A 
possible argument against its use in such clinical scena-
rio could be the observation that, in fact, it did not 
postpone the patient’s death very long. Nevertheless, it 
was employed only when the patient’s metabolic deran-
gement (renal function and hydration) was far advan-
ced, i.e., leading to a very critical and desperate clinical 
situation. Perhaps if ethanol injection had been  em-
ployed earlier, the clinical course could have been sli-
ghtly more favorable. 
Another point would be that other clinical measu-
res employed may confound the interpretation of the 
ethanol injection therapeutic effect. Saline hydration 
with large volumes, diuretics and bisphophonates de-
crease calcium levels but not PTH. PTH reduction oc-
curred only after ethanol injection, while all clinical 
measures had started earlier. Indeed, PTH decrease af-
ter ethanol injection resembles that observed after 
palliative resection, as observed in the graphic. It is re-
asonable to suppose that PTH decrease may have oc-
curred by the destruction of neoplastic cells.
One considerable problem for ethanol ablation is 
the volume to be injected. Larger volumes are less tole-
rated and add a significant risk of complications. Addi-
tionally, there is always the possibility to implant 
parathyroid carcinoma in the needle tract (16,17). In 
fact, this was a potential complication in the present 
case, but the procedure was considered the last availa-
ble palliative method at that time. 
Fortunately new palliation alternatives have been ad-
ded since 2003. Cinacalcet HCl proved to be an effecti-
ve drug in parathyroid carcinoma hypercalcemia, but the 
remarkable result obtained after anti-PTH immunothe-
rapy in one case with metastatic disease suggests that para-
thyroid immunology should deserve a deeper investigation. 
The result reported by Betea e col. in 2004 confirmed a 
previous report of the same group and it seems to open 
a promising window in the management of unresectable 
recurrent parathyroid carcinoma (11).
Evidently, a better understanding of the disease is 
mandatory, in order to develop more precise targeted 
therapies. A better prognosis is expected with the im-
provement in the management of hypercalcemia (18). 
Meanwhile, the present case adds a palliative therapeu-
tic option for this intriguing disease. Another observa-
tion is that a significant decrease in PTH levels right 
after the surgery cannot be an indicative of an effective 
resection. Intraoperative analysis of intact PTH may 
not indicate a complete resection and its role in para-
thyroid cancer surgery is questionable (1,2).
In conclusion, ultrasound guided percutaneous 
ethanol injection may be employed to palliate para-
thyroid carcinoma, with a transitory decrease in PTH 
and calcium levels.
REFERENCES
1. Mittendorf EA, McHenry CR. Parathyroid carcinoma. J Surg
Oncol. 2005;89:136-42.
2. Lumachi F, Basso SMM, Basso U. Parathyroid cancer: etiology, 
clinical presentation and treatment. Anticancer Res.
2006;26:4803-8.
3. Montenegro FLM, Tavares MR, Durazzo MD, Cernea CR, Cor-
deiro AC, Ferraz AR. Clinical suspicion and parathyroid carci-
noma management. S Paulo Med J. 2006;124(1):42-4.
4. Agarwal G, Prasad KK, Kar DK, Krishnani N, Pandey R, Mishra 
SK. Indian primary hyperpathyroidism patients with para-
thyroid carcinoma do not differ in clinicoinvestigative charac-
teristics from those with benign parathyroid pathology. World 
J Surg. 2006;30:732-42.
5. Kirby-Bott J, Lewis P, Harmer CL, Smellie WJB. One stage tre-
atment of parathyroid cancer. EJSO. 2005;31:78-83.
6. Cordeiro A, Montenegro FL, Kulcsar MA, DellaNegra LA, Tava-
res MR, Michaluart Jr P, et al. Parathyroid carcinoma. Am J 
Surg. 1998;175:52-5.
7. Dotzenrath C, Goretzki PE, Sarbia M, Cupisti K, Feldkamp J, 
Röher HD. Parathyroid carcinoma: problems in diagnosis and 
the need for radical surgery even in recurrent disease. EJSO.
2001;27:383-89.
8. Chow E, Tsang RW, Brierley JD, Filice S. Parathyroid carcino-
ma-the Princess Margaret Hospital experience. Int J Radiation
Oncology Biol Phys. 1998;41:569-72.
Arq Bras Endrocrinol Metab 2008;52/4 711
Ethanol injection for parathyroid carcinoma palliation
Montenegro et al.
c
o
p
yr
ig
h
t©
 A
BE
&
M
 t
o
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s
9. Koea JB Shaw JHF. Parathyroid carcinoma: biology and mana-
gement Surg Oncol. 1999;8:155-65.
10. Rodgers S, Perrier N. Parathyroid carcinoma. Curr Opin Oncol.
2006;18(1):16-22.
11. Betea D, Bradwell AR, Harvey TC, Mead GP, Schimdt-Gayk H, 
Ghaye B, et al. Hormonal and biochemical normalization and 
tumor shrinkage induced by anti-parathyroid hormone immu-
notherapy in a patient with metastatic parathyroid carcinoma. 
J Clin Endocrinol Metab. 2004;89:3413-20.
12. Shaha A, Shah J. Parathyroid carcinoma. A diagnostic and 
therapeutic challenge. Cancer. 1999;86(3):378-80.
13. Shane E. Parathyroid carcinoma. J Clin Endocrinol Metab. 
2001;86(2):485-93.
14. Kameyama K, Takami H. Proposal for the histological classifica-
tion of parathyroid carcinoma. Endocr Pathol. 2005;16(1):49-52.
15. Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, 
Thompson GB, et al. Indications, technique, and efficacy of al-
cohol injection of enlarged parathyroid glands in patients with 
primary hyperparathyroidism. Surgery. 1998;124:1011-20.
16. Agarwal G, Dhingra S, Mishra SK, Krishnani N. Implantation
of parathyroid carcinoma along fine needle aspiration track. 
Langenbecks Arch Surg. 2006;391:623-6.
17. Spinelli C, Bonadio AG, Berti P, Materazzi G, Miccoli P. Cuta-
neous spreading of parathyroid carcinoma after fine needle 
aspiration cytology. J Endocrinol Invest. 2000;23:255-7.
18. Vieira JGH, Ohe MN, Hauache OM, Oliveira UM, Delana JM, 
Gonçalves A, et al. Carcinoma de paratiróide. Arq Bras Endo-
crinol Metab. 2005;49(5):811-5.
Endereço para correspondência:
Fabio Luiz de Menezes Montenegro
Rua Apeninos, 1118, apto. 62
04104-021 São Paulo, SP
E-mail: fabiomonte@uol.com.br
